Proactive Investors - Run By Investors For Investors

Summit Therapeutics reduces first quarter losses

For the three months ended 30 April 2019, the antibiotic developer reported an operating loss of £4.8mln, down from £6.6mln a year ago
CEO Glyn Edwards said the firm was taking a leadership role in developing new classes of antibiotics to tackle resistance

Summit Therapeutics PLC (LON:SUMM) has reported a reduced loss for its first quarter and increased its cash reserves.

For the three months ended 30 April 2019, the AIM-listed firm reported an operating loss of £4.8mln, down from £6.6mln a year ago.

Revenues, meanwhile, fell to £249,000 from £3.87mln year-on-year, which the company said was related to its Sarepta licence and collaboration agreement following the group’s decision to discontinue development of its ezutromid treatment in June 2018.

READ: Summit Therapeutics soars as it hails potential of very early stage antibiotic

Summit also ended the quarter with a cash balance of £28.3mln compared to £26.9mln a year ago, adding that it had enough funds to support its operating expenses and capital expenditure until the end of January 2020.

The group’s chief executive, Glyn Edwards, said that the company was taking a leadership role in developing new classes of antibiotics which had the potential to combat the “rising threat” of antibiotic resistance.

"We believe these new class antibiotics have the potential to transform patient lives and that it is possible to show clear advantages over standard of care treatments and cost effectiveness during development. With this differentiated approach, we believe we will have the opportunity to be commercially successful”, he added.

The firm is currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which can cause diarrhoea, SMT-571 for Gonorrhoea and DDS-04 which is aiming to treat Enterobacteriaceae, a family of bacteria that includes salmonella.

In April, the company said the pre-clinical DDS-04 had successfully tackled Enterobacteriaceae in animals with urinary tract infections.

In early afternoon trading on Wednesday, Summit shares were steady at 23p.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use